131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
Status:
Available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This expanded access is the best available therapy/compassionate use designed to determine
the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory
neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher
priority. Patients may receive a range of doses depending on stem cell availability and tumor
involvement of bone marrow. Response rate, toxicity, and time to progression and death will
be evaluated.